They reported that alternative pathways are activated in AKT-inhibitors-treated cells for escaping the inhibition of the cell growth, i.e., the levels of phosphorylated glycogen synthase kinase 3 beta were reduced in the Hs578T cell line of breast cancer [14]. This evidence concerns the gene AKT1 and breast carcinoma.